Rotigotine
3 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
3
Ongoing
1
Recruiting
1
Completed
2
Sites
4
Countries
1
Endpoints
29
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 29 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 11 of 29 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
3
2
2
1
1
1
1
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
3 of 3
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT04937452Dopaminergic Therapy for Frontotemporal Dementia Patients | Rotigotine Frontotemporal dementia | Age 40-80 | Ph 2 | Completed | 3 | Dec 2023 | 1 | |
| DOPADEffects of Dopaminergic Therapy in Patients With Alzheimer's Disease | Rotigotine Alzheimer’s disease | Alzheimer's disease | Ph 2 | Completed | 1 | Nov 2018 | 4 | |
| DOPAD-3A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease | Rotigotine Alzheimer’s disease | Alzheimer's disease | Ph 3 | Recruiting | 1 | Jul 2025 | - |
Showing 1-3 of 3 trials